Gelsolin: a new biomarker of disease activity in SLE patients associated with HDL-c.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Affiliation:
      Autoimmune Diseases Unit, Internal Medicine Department, 'Sant Joan' University Hospital (Reus, Spain), Spain
      Institut Investigació Sanitaria Pere Virgili (IISPV), Universitat Rovira i Virgili (URV), Reus, Spain
      Unitat de Recerca de Lipids i Arteriosclerosis (URLA), 'Sant Joan' University Hospital (Reus-Spain), Spain
      Centre for Omic Science, Joint Unit Universitat Rovira i Virgili-Eurecat, Spain
      Department of Electronic Engineering, Universitat Rovira i Virgili (URV), Reus, Spain, Rovira i Virgili University, IISPV, Spain
      Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
    • Subject Terms:
    • Subject Terms:
    • Abstract:
      Objectives To identify potential biomarkers of disease activity analysing the proteome of high-density lipoprotein (HDL) particles from SLE patients in clinical remission and when they develop a flare compared with a healthy control group. Methods Quantitative proteomic analyses of purified HDL were performed using Tandem Mass Tag isobaric tag-labelling and nanoLC-Orbitrap (nLC-MS/MS) from nine SLE patients in clinical remission when they developed a flare and from nine healthy controls (9–9-9). We verified the identified proteins by Western blot and ELISA in a cohort of 104 SLE women patients, 46 healthy women and 14 SLE patients when a flare developed. Results We found 17 proteins with a significant fold-change (>1.1) compared with the control group. In lupus patients experiencing a flare compared with those in remission, we identified four proteins with a significant fold-change (C4, Indian Hedgehog protein, S100A8 and gelsolin). Plasma gelsolin (pGSN) levels were decreased in the 104 SLE patients (176.02(74.9) mcg/l) compared with the control group (217.13(86.7) mcg/l); P =0.005 and when they developed a clinical flare (104.84(41.7) mcg/l); P =0.002). pGSN levels were associated with HDL cholesterol levels (r = 0.316, P <0.001). Antimalarial treated patients showed significant higher levels of pGSN (214.56(88.94) mcg/l regarding 170.35(66.36) mcg/l); P = 0.017. Conclusion Decreased pGSN are associated with clinical disease activity in SLE patients. Antimalarial treatment and HDL cholesterol are associated with higher levels of pGSN.
    • Journal Subset:
      Biomedical; Europe; UK & Ireland
    • ISSN:
      1462-0324
    • Publication Date:
      20200229
    • Publication Date:
      20200304
    • DOI:
      http://dx.doi.org/10.1093/rheumatology/kez293
    • Accession Number:
      141923314
  • Citations
    • ABNT:
      PARRA, S. et al. Gelsolin: a new biomarker of disease activity in SLE patients associated with HDL-c. Rheumatology, [s. l.], v. 59, n. 3, p. 650–661, 2020. DOI 10.1093/rheumatology/kez293. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=141923314. Acesso em: 2 jul. 2020.
    • AMA:
      Parra S, Heras M, Herrero P, et al. Gelsolin: a new biomarker of disease activity in SLE patients associated with HDL-c. Rheumatology. 2020;59(3):650-661. doi:10.1093/rheumatology/kez293.
    • AMA11:
      Parra S, Heras M, Herrero P, et al. Gelsolin: a new biomarker of disease activity in SLE patients associated with HDL-c. Rheumatology. 2020;59(3):650-661. doi:10.1093/rheumatology/kez293
    • APA:
      Parra, S., Heras, M., Herrero, P., Amigó, N., Garcés, E., Girona, J., Correig, X., Canela, N., & Castro, A. (2020). Gelsolin: a new biomarker of disease activity in SLE patients associated with HDL-c. Rheumatology, 59(3), 650–661. https://doi.org/10.1093/rheumatology/kez293
    • Chicago/Turabian: Author-Date:
      Parra, Sandra, Mercedes Heras, Pol Herrero, Nuria Amigó, Esperanza Garcés, Josefa Girona, Xavier Correig, Nuria Canela, and Antoni Castro. 2020. “Gelsolin: A New Biomarker of Disease Activity in SLE Patients Associated with HDL-C.” Rheumatology 59 (3): 650–61. doi:10.1093/rheumatology/kez293.
    • Harvard:
      Parra, S. et al. (2020) ‘Gelsolin: a new biomarker of disease activity in SLE patients associated with HDL-c’, Rheumatology, 59(3), pp. 650–661. doi: 10.1093/rheumatology/kez293.
    • Harvard: Australian:
      Parra, S, Heras, M, Herrero, P, Amigó, N, Garcés, E, Girona, J, Correig, X, Canela, N & Castro, A 2020, ‘Gelsolin: a new biomarker of disease activity in SLE patients associated with HDL-c’, Rheumatology, vol. 59, no. 3, pp. 650–661, viewed 2 July 2020, .
    • MLA:
      Parra, Sandra, et al. “Gelsolin: A New Biomarker of Disease Activity in SLE Patients Associated with HDL-C.” Rheumatology, vol. 59, no. 3, Mar. 2020, pp. 650–661. EBSCOhost, doi:10.1093/rheumatology/kez293.
    • Chicago/Turabian: Humanities:
      Parra, Sandra, Mercedes Heras, Pol Herrero, Nuria Amigó, Esperanza Garcés, Josefa Girona, Xavier Correig, Nuria Canela, and Antoni Castro. “Gelsolin: A New Biomarker of Disease Activity in SLE Patients Associated with HDL-C.” Rheumatology 59, no. 3 (March 2020): 650–61. doi:10.1093/rheumatology/kez293.
    • Vancouver/ICMJE:
      Parra S, Heras M, Herrero P, Amigó N, Garcés E, Girona J, et al. Gelsolin: a new biomarker of disease activity in SLE patients associated with HDL-c. Rheumatology [Internet]. 2020 Mar [cited 2020 Jul 2];59(3):650–61. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=141923314